Pfizer Company Profile

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

PFIZER has one hundred and eighty-nine approved drugs.

There are thirty-seven US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are seven hundred and fifty-five patent family members on PFIZER drugs in sixty-six countries and two hundred and thirty-nine supplementary protection certificates in nineteen countries.

International Patents:	755
US Patents:	37
Tradenames:	154
Ingredients:	125
NDAs:	189
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	10,723,730	See Plans and Pricing	Y	Y		See Plans and Pricing
Pfizer	TETRACYN	procaine hydrochloride; tetracycline hydrochloride	INJECTABLE;INJECTION	060285-002	Approved Prior to Jan 1, 1982		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
Pfizer	ATARAX	hydroxyzine hydrochloride	TABLET;ORAL	010392-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No		See Plans and Pricing				See Plans and Pricing
Pfizer	PROVERA	medroxyprogesterone acetate	TABLET;ORAL	011839-004	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes		See Plans and Pricing				See Plans and Pricing
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No	9,549,929	See Plans and Pricing				See Plans and Pricing
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	RE47739	See Plans and Pricing	Y	Y		See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-002	Jul 6, 1995	4,127,118	See Plans and Pricing
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-003	Aug 4, 1997	5,104,888	See Plans and Pricing
Pfizer	GLYSET	miglitol	TABLET;ORAL	020682-001	Dec 18, 1996	4,639,436	See Plans and Pricing
Pfizer	HEMABATE	carboprost tromethamine	INJECTABLE;INJECTION	017989-001	Approved Prior to Jan 1, 1982	3,728,382	See Plans and Pricing
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994	5,591,454	See Plans and Pricing
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-003	Aug 4, 1997	4,572,912	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2005-12-21
➤ Subscribe	Injection	2 mg/mL, 300 mL bag	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	1 g	➤ Subscribe	2005-08-23
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Oral Suspension	100 mg/5 mL	➤ Subscribe	2009-08-03
➤ Subscribe	Injection	2 mg/mL, 100 mL bag	➤ Subscribe	2009-12-29
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	006227	See Plans and Pricing
Portugal	2630146	See Plans and Pricing
Malaysia	134818	See Plans and Pricing
Israel	241400	See Plans and Pricing
Hungary	E037192	See Plans and Pricing
Cuba	23220	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try it Free
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0253738	C960002	Netherlands	See Plans and Pricing	PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
1848414	CA 2016 00033	Denmark	See Plans and Pricing	PRODUCT NAME: OSIMERTINIB; REG. NO/DATE: EU/1/16/1086/001-0002 20160204
0328535	96C0021	Belgium	See Plans and Pricing	PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0480717	98C0025	Belgium	See Plans and Pricing	PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0402407	97C0005	Belgium	See Plans and Pricing	PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
1470124	PA2017013,C1470124	Lithuania	See Plans and Pricing	PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.